Immunome

Immunome Set to Acquire Atreca’s Antibody-Related Assets in a Move to Revolutionize Cancer Therapies

EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a leading biotech firm specializing in cancer therapies, recently announced its plan to purchase a trove of antibody-related assets from Atreca, Inc. (Nasdaq: …

Immunome Set to Acquire Atreca’s Antibody-Related Assets in a Move to Revolutionize Cancer Therapies Read More



Aclaris Therapeutics

Aclaris Therapeutics Advances ATI-1777 into Phase 2b Trial, Plans Workforce Reduction to Preserve Capital

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is making strategic moves, announcing several updates this week including promising trial results, a shift in drug development focus, and a significant …

Aclaris Therapeutics Advances ATI-1777 into Phase 2b Trial, Plans Workforce Reduction to Preserve Capital Read More
Ocugen

Ocugen’s OCU400 Earns FDA’s RMAT Designation, Enhancing Prospects for Retinitis Pigmentosa Treatment

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a Pennsylvania-based biopharmaceutical company, has scored a significant regulatory milestone this week with the U.S. Food and Drug Administration (FDA) granting Regenerative Medicine …

Ocugen’s OCU400 Earns FDA’s RMAT Designation, Enhancing Prospects for Retinitis Pigmentosa Treatment Read More